Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCQ | Q04759 | 9/20 | 0.38 |
| ▸ | PRKCD | Q05655 | 8/20 | 0.36 |
| ▸ | JAK3 | P52333 | 2/20 | 0.35 |
| ▸ | JAK2 | O60674 | 1/20 | 0.35 |
| ▸ | MELK | Q14680 | 2/20 | 0.35 |
| ▸ | JAK1 | P23458 | 1/20 | 0.35 |
| ▸ | TYK2 | P29597 | 1/20 | 0.35 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.34 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.34 |
| ▸ | SRC | P12931 | 3/20 | 0.33 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.33 |
| ▸ | FYN | P06241 | 1/20 | 0.32 |
| ▸ | CDK1 | P06493 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10099306 | 0.84 | MAPT (0.35) | JAK3JAK1 | |
| SCHEMBL10099288 | 0.82 | PDE5A (0.30) | — | |
| SCHEMBL566930 | 0.81 | ACHE (0.41) | JAK1SRC | |
| SCHEMBL21954829 | 0.81 | DGAT1 (0.36) | — | |
| SCHEMBL10099173 | 0.80 | JAK3 (0.45) | JAK3JAK2JAK1IRAK4 | |
| SCHEMBL31124391 | 0.79 | SCN9A (0.39) | IRAK4 | |
| SCHEMBL10099169 | 0.77 | EGFR (0.39) | SRC | |
| SCHEMBL21858994 | 0.77 | TBK1 (0.36) | — | |
| SCHEMBL14697518 | 0.77 | PDE4B (0.35) | CDK1 | |
| SCHEMBL14697556 | 0.76 | TBK1 (0.38) | CDK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120034250-A1 | CONDENSED PYRROLOPYRIDINE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2012-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120034250-A1 | CONDENSED PYRROLOPYRIDINE DERIVATIVE | JAK2, JAK1, JAK3 | PRKCQ 155/4885PRKCD 165/4885JAK3 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.